<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0120-2448</journal-id>
<journal-title><![CDATA[Acta Medica Colombiana]]></journal-title>
<abbrev-journal-title><![CDATA[Acta Med Colomb]]></abbrev-journal-title>
<issn>0120-2448</issn>
<publisher>
<publisher-name><![CDATA[Asociacion Colombiana de Medicina Interna]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0120-24482021000300032</article-id>
<article-id pub-id-type="doi">10.36104/amc.2021.2028</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Therapeutic apheresis. With a new hydroxyethyl starch (Voluven) replacement technique]]></article-title>
<article-title xml:lang="es"><![CDATA[Aféresis terapéutica. Con una nueva técnica de reposición con hidroxietil almidón (voluven)]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[TORRES-SERRANO]]></surname>
<given-names><![CDATA[RODOLFO EDUARDO]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[ROSELLI-SANMARTÍN]]></surname>
<given-names><![CDATA[CARLOS]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[OLIVARES-ALGARÍN]]></surname>
<given-names><![CDATA[CARLOS ROBERTO]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[OLIVARES-ALGARÍN]]></surname>
<given-names><![CDATA[ORLANDO]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[MONTERO-CETINA]]></surname>
<given-names><![CDATA[CAMILO]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[ZAMBRANO-GONZÁLEZ]]></surname>
<given-names><![CDATA[DIANA MARCELA]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[SUÁREZ-MARTÍNEZ]]></surname>
<given-names><![CDATA[ARNOLDO JOSÉ]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[MADARIAGA-CAROCCI]]></surname>
<given-names><![CDATA[CARLOS]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital de San José Fundación Universitaria de Ciencias de la Salud ]]></institution>
<addr-line><![CDATA[Bogotá D.C]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Hospital de San José Fundación Universitaria de Ciencias de la Salud Asistente Departamento de Nefrología-Medicina Interna]]></institution>
<addr-line><![CDATA[Bogotá D.C]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Hospital de San José Fundación Universitaria de Ciencias de la Salud ]]></institution>
<addr-line><![CDATA[Bogotá D.C]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Hospital de San José Fundación Universitaria de Ciencias de la Salud ]]></institution>
<addr-line><![CDATA[Bogotá D.C]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af5">
<institution><![CDATA[,Hospital de San José Fundación Universitaria de Ciencias de la Salud ]]></institution>
<addr-line><![CDATA[Bogotá D.C]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af6">
<institution><![CDATA[,Hospital de San José Fundación Universitaria de Ciencias de la Salud ]]></institution>
<addr-line><![CDATA[Bogotá D.C]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af7">
<institution><![CDATA[,Hospital de San José Fundación Universitaria de Ciencias de la Salud ]]></institution>
<addr-line><![CDATA[Bogotá D.C]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af8">
<institution><![CDATA[,Hospital de San José Fundación Universitaria de Ciencias de la Salud ]]></institution>
<addr-line><![CDATA[Bogotá D.C]]></addr-line>
<country>Colombia</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>09</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>09</month>
<year>2021</year>
</pub-date>
<volume>46</volume>
<numero>3</numero>
<fpage>32</fpage>
<lpage>38</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_arttext&amp;pid=S0120-24482021000300032&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_abstract&amp;pid=S0120-24482021000300032&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_pdf&amp;pid=S0120-24482021000300032&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Introduction: while plasma apheresis is a longstanding, widely used treatment for renal and non-renal indications, with different levels of evidence described by the American Society for Apheresis, there are few studies in the literature comparing the use of different replacement solutions (crystalloids, colloids, plasma, albumin) with regard to their clinical and paraclinical response, specifically in kidney function results.  Objective: to describe the experience of patients undergoing plasma apheresis in a quaternary care institution with a new replacement solution strategy using Voluven, emphasizing kidney function and safety outcomes.  Methods: a case series which included patients treated with plasmapheresis who were admitted to the nephrology service at Hospital San José between January 2012 and April 2019. A descriptive analysis was performed.  Results: 608 plasmapheresis sessions were performed. The most common indication was acute humoral rejection in kidney transplantation. At the end of treatment, patients receiving plasma and hydroxyethyl starch (HES) had a similar proportion of hypocalcemia and thrombocytopenia. Kidney function tests remained normal after treatment.  Conclusion: our study's comparison between the different plasma replacement fluids (albumin or HES) with regard to the side effects of therapeutic apheresis such as blood disorders (altered coagulation factors, thrombocytopenia or anemia), hypocalcemia or possible kidney function disorders, showed no major disorders and preserved kidney function during treatment. In addition, we found that HES did not cause acute kidney injury; on the contrary, kidney function was stable. Therefore, its use should be considered as a low-cost product with excellent clinical results. (Acta Med Colomb 2021; 46. DOI:https://doi.org/10.36104/amc.2021.2028).]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Introducción: la aféresis plasmática, ampliamente utilizada, con indicaciones renales y no renales, así mismo con diferentes niveles de evidencia descritos por la Sociedad Americana de Aféresis, siendo un tratamiento antiguo y muy utilizado, en la literatura se disponen de escasos estudios que comparen el uso de las diferentes soluciones de reposición (cristaloides, coloides, plasma, albúmina) en cuanto a su respuesta clínica y paraclínica, específicamente en resultados de la función renal.  Objetivo: describir la experiencia de pacientes llevados a aféresis plasmática en una institución de cuarto nivel, haciendo énfasis en los desenlaces de función renal y seguridad, con una nueva estrategia de solución de reposición con voluven.  Métodos: estudio tipo serie de casos, se incluyeron pacientes tratados con plasmaféresis, quienes ingresaron entre enero 2012 y abril 2019 al servicio de nefrología del Hospital San José. Se realizó un análisis descriptivo.  Resultados: se realizaron 608 sesiones de plasmaféresis. La indicación más frecuente el rechazo humoral agudo en el trasplante renal. Al final del periodo de tratamiento, los pacientes en plasma e hidroxietil almidón (hydroxyethyl starch, HES por sus siglas en inglés) presentaron similar proporción de hipocalcemia y trombocitopenia, las pruebas de función renal se conservan normales después del tratamiento.  Conclusión: los efectos secundarios de la aféresis terapéutica como los trastornos hematológicos (alteración de los factores de coagulación, trombocitopenia o anemia), además de hipocalcemia, o posibles alteraciones de la función renal comparados entre los diferentes líquidos de reemplazo plasmático, albúmina o HES, en nuestro trabajo demostró que las alteraciones no son mayores y la función renal se mantiene conservada durante la terapia, además, se encontró que el uso de HES no generó lesión renal aguda, al contrario, se observa estabilidad de la función renal, por lo tanto se debe considerar su uso, siendo un producto de bajo costo, con excelentes resultados clínicos. (Acta Med Colomb 2021; 46. DOI:https://doi.org/10.36104/amc.2021.2028).]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[apheresis]]></kwd>
<kwd lng="en"><![CDATA[plasmapheresis]]></kwd>
<kwd lng="en"><![CDATA[therapeutic apheresis]]></kwd>
<kwd lng="en"><![CDATA[hydroxyethyl starch]]></kwd>
<kwd lng="en"><![CDATA[kidney failure]]></kwd>
<kwd lng="es"><![CDATA[aféresis]]></kwd>
<kwd lng="es"><![CDATA[plasmaféresis]]></kwd>
<kwd lng="es"><![CDATA[aféresis terapéutica]]></kwd>
<kwd lng="es"><![CDATA[hidroxietil almidón]]></kwd>
<kwd lng="es"><![CDATA[falla renal]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Abel]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Rowntree]]></surname>
<given-names><![CDATA[LC]]></given-names>
</name>
<name>
<surname><![CDATA[Turner]]></surname>
<given-names><![CDATA[BB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Plasma removal with return of corpuscles]]></article-title>
<source><![CDATA[Journal of Pharmacology and Experimental Therapeutics]]></source>
<year>1914</year>
<volume>5</volume>
<page-range>625-41</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Siami]]></surname>
<given-names><![CDATA[GA]]></given-names>
</name>
<name>
<surname><![CDATA[Siami]]></surname>
<given-names><![CDATA[FS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Membrane plasmapheresis in the United States: a review over the last 20 years]]></article-title>
<source><![CDATA[Therapeutic Apheresis]]></source>
<year>2001</year>
<volume>5</volume>
<page-range>315-20</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Restrepo]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Márquez]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Sanz]]></surname>
<given-names><![CDATA[MF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Therapeutic plasma exchange: types, techniques and indications in internal medicine]]></article-title>
<source><![CDATA[Acta Médica Colombiana]]></source>
<year></year>
<volume>34</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Agreda-Vásquez]]></surname>
<given-names><![CDATA[GP]]></given-names>
</name>
<name>
<surname><![CDATA[Espinosa-Poblano]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Sánchez-Guerrero]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
<name>
<surname><![CDATA[Crespo-Solís]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Cabrera-Vásquez]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[López-Salmorán]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Barajas]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Starch and albumin mixture as replacement fluid in therapeutic plasma exchange is safe and effective]]></article-title>
<source><![CDATA[J Clin Apher]]></source>
<year>2008</year>
<volume>23</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>163-7</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Myburgh]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Finfer]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Bellomo]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Billot]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Cass]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Gattas]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hydroxy-ethyl Starch or Saline for Fluid Resuscitation in Intensive Care]]></article-title>
<source><![CDATA[New England Journal of Medicine]]></source>
<year>2012</year>
<volume>367</volume>
<numero>20</numero>
<issue>20</issue>
<page-range>1901-11</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Moake]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Thrombotic microangiopathies: multimers, metalloprotease, and beyond]]></article-title>
<source><![CDATA[Clinical and Translational Science]]></source>
<year>2009</year>
<volume>2</volume>
<page-range>366-73</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rock]]></surname>
<given-names><![CDATA[GA]]></given-names>
</name>
<name>
<surname><![CDATA[Shumak]]></surname>
<given-names><![CDATA[KH]]></given-names>
</name>
<name>
<surname><![CDATA[Buskard]]></surname>
<given-names><![CDATA[NA]]></given-names>
</name>
<name>
<surname><![CDATA[Blanchette]]></surname>
<given-names><![CDATA[VS]]></given-names>
</name>
<name>
<surname><![CDATA[Kelton]]></surname>
<given-names><![CDATA[JG]]></given-names>
</name>
<name>
<surname><![CDATA[Nair]]></surname>
<given-names><![CDATA[RC]]></given-names>
</name>
<name>
<surname><![CDATA[Spasoff]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparison of plasma exchange and plasma infusion in the treatment of thrombotic thrombocytopenic purpura]]></article-title>
<source><![CDATA[Canadian Apheresis Study Group New England Journal of Medicine]]></source>
<year>1991</year>
<volume>325</volume>
<page-range>393-7</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Winters]]></surname>
<given-names><![CDATA[Hollie M Reeves Jeffrey L]]></given-names>
</name>
</person-group>
<source><![CDATA[The mechanisms of action of plasma exchange]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="">
<source><![CDATA[Acute Therapy Systems plasmaFlux® P1dry/P2dry Membrane Plasma Separation (MPS)/ Therapeutic Plasma Exchange (TPE) with the multiFiltrate]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pineda]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Selective therapeutic extraction of plasma constituents, revisited]]></article-title>
<source><![CDATA[Transfusion]]></source>
<year>1999</year>
<volume>39</volume>
<page-range>671-3</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bloch]]></surname>
<given-names><![CDATA[KJ]]></given-names>
</name>
<name>
<surname><![CDATA[Maki]]></surname>
<given-names><![CDATA[DG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hyperviscosity syndromes associated with immunoglobulin abnormalities]]></article-title>
<source><![CDATA[Seminars in Hematology]]></source>
<year>1973</year>
<volume>10</volume>
<page-range>113-24</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Torres-Serrano Rodolfo]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Diana]]></surname>
<given-names><![CDATA[Zambrano]]></given-names>
</name>
<name>
<surname><![CDATA[Katerine]]></surname>
<given-names><![CDATA[Caceres]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Características histológicas del rechazo humoral agudo, respuesta al tratamiento y pronóstico, en una población de pacientes del Hospital San José. Bogotá, Colombia. Resúmenes del XXIII Congreso Latinoamericano y del Caribe de Trasplante]]></article-title>
<source><![CDATA[Revista Mexicana de Trasplantes]]></source>
<year>2015</year>
<volume>4</volume>
<page-range>S111</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mokrzycki]]></surname>
<given-names><![CDATA[Michele H]]></given-names>
</name>
<name>
<surname><![CDATA[Balogun]]></surname>
<given-names><![CDATA[Rasheed A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Apheresis: A Review of Complications and Recommendations for Prevention and Management]]></article-title>
<source><![CDATA[Journal of Clinical Apheresis]]></source>
<year>2011</year>
<volume>26</volume>
<page-range>243-8</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tek]]></surname>
<given-names><![CDATA[Ibrahim]]></given-names>
</name>
<name>
<surname><![CDATA[Arslan]]></surname>
<given-names><![CDATA[Onder]]></given-names>
</name>
<name>
<surname><![CDATA[Arat]]></surname>
<given-names><![CDATA[Mutlu]]></given-names>
</name>
<name>
<surname><![CDATA[Ozcan]]></surname>
<given-names><![CDATA[Muhit]]></given-names>
</name>
<name>
<surname><![CDATA[Akdag]]></surname>
<given-names><![CDATA[Beyza]]></given-names>
</name>
<name>
<surname><![CDATA[Ilhan]]></surname>
<given-names><![CDATA[Osman]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effects of replacement fluids on coagulation system used for therapeutic plasma exchange]]></article-title>
<source><![CDATA[Transfusion and Apheresis Science]]></source>
<year>2003</year>
<volume>28</volume>
<page-range>3-7</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Keith]]></surname>
<given-names><![CDATA[Douglas S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Therapeutic Apheresis in Renal Transplantation; Current Practices]]></article-title>
<source><![CDATA[Journal of Clinical Apheresis]]></source>
<year>2014</year>
<volume>29</volume>
<page-range>206-10</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
